Biognosys raises USD 5 million

Schlieren ZH – Biognosys has secured USD 5 million in a financing round. The Schlieren-based biotechnology company will use the new funds to develop innovative methods in proteomics.

Biognosys raised USD 5 million in an extended series C financing round and secured new investors. Biognosys, which specialises in proteomics, develops methods for researching proteomes, or the entire complement of proteins in an entity such as a cell. This provides the foundation for developing innovative treatments.

Top pharma and biotech companies including NovartisAstraZeneca and Moderna Therapeutics and leading academic institutions have recognised Biognosys’ specialist expertise in proteomics.

The company will use the new funds to accelerate the development of next generation proteomics workflows and products for high-content and high-throughput protein analysis, according to a statement. It also plans to extend its commercial operations.

"The feedback that we get from our customers shows there is a shift in the perception of proteomics, away from a highly specialized analytical tool and towards a universally applicable technology for mode of action studies and biomarker development,” commented Oliver Rinner, CEO and co-founder of Biognosys.

According to Rinner, the new funds will help Biognosys to further extend its technological lead, to accelerate the development of new products and to better address the life science research market outside the classical proteomics field.

Biognosys was founded in 2008 as a spin-off from the Federal Institute of Technology in Zurich (ETH). It is headquartered in the Bio-Technopark Schlieren-Zurich

Interactive Industry Map
Bi-Monthly Updates

Get our industry newsletters

Clients and cases
+41 44 254 59 59
6:59 pm
+1 415 655 1045
6:59 pm
+86 21 6235 1889
6:59 pm

Subscribe to our newsletter (englisch)